| Literature DB >> 22265862 |
Shun Fujimaki1, Yasunobu Matsuda, Toshifumi Wakai, Ayumi Sanpei, Masayuki Kubota, Masaaki Takamura, Satoshi Yamagiwa, Masahiko Yano, Shogo Ohkoshi, Yutaka Aoyagi.
Abstract
Sorafenib is a multi-kinase inhibitor applicable to hepatocellular carcinoma (HCC), but its limited therapeutic effects are a major problem to be solved. Here, we show that blockade of ataxia telangiectasia mutated (ATM) improves the antitumor effects of sorafenib. When hepatoma cell lines HepG2 and PLC/PRF/5 were treated with sorafenib plus ATM small inhibitory RNAs, ATM inhibitor KU55933 or caffeine, Akt signaling was suppressed and the cytotoxic effects were significantly potentiated. Moreover, ATM inhibition effectively suppressed the sorafenib-induced cell migration. Taken together, manipulation of ATM activity might be a useful strategy for improving sorafenib treatment of HCC.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22265862 DOI： 10.1016/j.canlet.2011.12.043
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679